ERBB2 and breast cancer: Routine pathological assessment of the prognostic and predictive biological factors of breast cancer, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, and tumor grade, determine the treatment decision and the response of breast cancers to therapy (1–4).